Similar to PD-1-blocking antibodies, the blockade of PD-L1 could have beneficial effects in the combination with CAR-T cells, as demonstrated by the successful eradication of rhabdomyosarcoma in an orthotopic murine model by novel FGF receptor 4 (FGFR4, CD334)–specific CAR-T cells [78]. The gene discussed is FGFR4; the disease is rhabdomyosarcoma.